NCT02933320 - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

March 19, 2020

Study Completion Date

March 19, 2020

Conditions

B-cell LymphomaChronic Lymphocytic LeukaemiaWaldenström Macroglobulinemia

Interventions

BIOLOGICAL

BI-1206 single agent dose escalation phase

BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.

BIOLOGICAL

Combination of BI-1206 with rituximab escalation phase

An investigation of combination treatment of BI-1206 with rituximab.

BIOLOGICAL

BI-1206 single agent expansion phase

BI-1206 single agent expansion phase at the RP2D.

BIOLOGICAL

Combination of BI-1206 with rituximab expansion phase

BI-1206 in combination with rituximab at the RP2D.

Trial Locations (5)

LE1 5WW

Leicester Royal Infirmary, Leicester

M20 4BX

Christie Hospital, Manchester

OX3 7LE

Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford

PL6 8DH

Derriford Hospital, Plymouth

S016 6YD

University Hospital Southampton NHS Foundation Trust, Southampton